Literature DB >> 32078589

Notes from the Field: Characteristics of Million Hearts Hypertension Control Champions, 2012-2019.

Matthew D Ritchey, Judy Hannan, Hilary K Wall, Mary G George, Laurence S Sperling.   

Abstract

Entities:  

Year:  2020        PMID: 32078589      PMCID: PMC7043391          DOI: 10.15585/mmwr.mm6907a5

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


× No keyword cloud information.
Million Hearts is a national initiative co-led by CDC and the Centers for Medicare & Medicaid Services that aims to prevent 1 million heart attacks, strokes, and other related acute cardiovascular events by 2022 (,). On November 19, 2019, the initiative recognized 17 Million Hearts Hypertension Control Champions for achieving ≥80% blood pressure control rates among their patients with hypertension. These Champions include clinicians, practices, health centers, and health systems from 15 states that provide care for 201,045 adult patients, approximately one third (68,019) of whom have hypertension. The Hypertension Control Challenge is held annually to identify new Champions, with a call for applications in the spring, review and vetting in the summer, and announcement of Champions in the late fall. Since 2012, Million Hearts has recognized 118 Champions from 36 states and the District of Columbia who care for more than 15 million adult patients, including 5 million with hypertension (Table).* Hypertension is a leading modifiable risk factor for heart disease and stroke (–). In light of this risk and the potential impact on preventing cardiovascular events by controlling hypertension, Million Hearts focuses on improving control of blood pressure among persons with hypertension. The Hypertension Control Challenge is an opportunity to call attention to the importance of controlling blood pressure in preventing cardiovascular disease and to create a sense of urgency around hypertension control, encouraging clinicians and health systems to share their achievements and promote their successful strategies. To be eligible for recognition as a 2019 Champion, applicants were required to have an adult patient population of at least 500 persons and a hypertension control rate of 80% or higher among patients aged 18–85 years with diagnosed hypertension during a 12-month reporting period starting on or after January 1, 2018. Hypertension control was defined as a last blood pressure reading of <140/90 mm Hg, which aligns with current clinical performance measure specifications used by the health care sector to track progress in hypertension control. Using definitions consistent with these specifications nationally, approximately 75 million adults have hypertension, and only one half of these persons have their hypertension controlled (). Applicants submitted information on their patient population size, demographic characteristics, and hypertension prevalence and control rates. Applicants’ eligibility status was assessed, and a subset of their submitted hypertension control data was validated through a formal external review. All 17 Champions identified in 2019 were from the private sector, including nine (53%) who had a rural-only service area and five health centers funded by the Health Resources and Services Administration. Among the 17 Champions, the median adult patient population size was 2,639 (range = 574–137,415) (Table). The median hypertension prevalence was 34% (range = 21%–52%), and the median hypertension control rate was 84% (range = 80%–98%).
TABLE

Characteristics of patient populations treated by Million Hearts Hypertension Control Champions, 2012–2019

Characteristic20192012–2018*Total
Champions (total no.)
17
101
118
States represented, no.
15
35
37§
Sector, no.
Private
17
98
115
Federal
0
3
3
Service area type, no. (%)
Urban
7 (41)
50 (50)
57 (48)
Rural
9 (53)
19 (19)
28 (24)
Both urban and rural
1 (6)
32 (32)
33 (28)
HRSA-funded health centers, no. (%)
5 (29)
31 (31)
36 (31)
No. of adult patients treated annually
Median (range)
2,639 (574–137,415)
6,682 (550–6,100,000)
5,706 (550–6,100,000)
Total
201,045
15,049,386
15,250,431
Self-reported patient population characteristics, median percentage (no. of Champions with response; percentage range)
Minority**
20 (17; 0–92)
27 (98; 0–100)
25 (115; 0–100)
English as a second language
3 (17; 0–85)
3 (96; 0–95)
3 (113; 0–95)
Medicaid beneficiary
15 (17; 0–75)
18 (98; 0–85)
17 (115; 0–85)
Uninsured
5 (17; 0–21)
5 (18; 0–33)
5 (35; 0–33)
No. of adult patients with hypertension treated annually
Median among Champions (range)
838 (189–45,704)
1,676 (96–2,900,000)
1,474 (96–2,900,000)
Total
68,019
5,023,114
5,091,133
Median hypertension prevalence, % (range)
34 (21–52)
30 (7–86)
31 (7–86)
Median blood pressure control rate,†† % (range) 84 (80–98)80 (70–99)81 (70–99)

Abbreviation: HRSA = Health Resources and Services Administration.

* Excludes 2016.

† California, Connecticut, Florida, Illinois, Iowa, Kentucky, New Jersey, New York, Pennsylvania, Rhode Island, Texas, Utah, Virginia, Washington, and Wisconsin.

§ In addition to the states in which 2019 Champions were recognized, also includes the District of Columbia, Colorado, Georgia, Hawaii, Kansas, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, New Hampshire, New Mexico, North Dakota, Ohio, Oklahoma, Oregon, South Carolina, Tennessee, West Virginia, and Wyoming; the U.S. Department of Veterans Affairs was also recognized as a Champion in 2013 and has coverage throughout the United States.

¶ Information on HRSA-funded health center status was not consistently collected during 2012–2017; therefore, it might be underreported.

** Minority status of the patient population was determined by the applicant. No formal definition was recommended for use.

†† During 2012–2017, Champions were recognized for having blood pressure control rates of 70% or higher.

Abbreviation: HRSA = Health Resources and Services Administration. * Excludes 2016. † California, Connecticut, Florida, Illinois, Iowa, Kentucky, New Jersey, New York, Pennsylvania, Rhode Island, Texas, Utah, Virginia, Washington, and Wisconsin. § In addition to the states in which 2019 Champions were recognized, also includes the District of Columbia, Colorado, Georgia, Hawaii, Kansas, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, New Hampshire, New Mexico, North Dakota, Ohio, Oklahoma, Oregon, South Carolina, Tennessee, West Virginia, and Wyoming; the U.S. Department of Veterans Affairs was also recognized as a Champion in 2013 and has coverage throughout the United States. ¶ Information on HRSA-funded health center status was not consistently collected during 2012–2017; therefore, it might be underreported. ** Minority status of the patient population was determined by the applicant. No formal definition was recommended for use. †† During 2012–2017, Champions were recognized for having blood pressure control rates of 70% or higher. This national recognition program demonstrates that achieving high hypertension control rates is possible across a range of health care settings and among patient populations at high risk for uncontrolled hypertension (–). Various strategies have been reported by past Champions that supported their achievement of high control rates (). Specific strategies highlighted by this year’s Champions included identifying a clinician within their organization who was dedicated to leading their hypertension management quality improvement efforts, arranging frequent office visits until blood pressure control was achieved, using hypertension treatment protocols and electronic health record–supported patient registries to guide patient treatment and follow-up, and providing clinician feedback through performance reports. In addition, Champions reported engaging patients in self-measured blood pressure monitoring to assess progress, inform decision-making, and encourage treatment adherence. A broader application of the strategies used by the Champions identified through the Hypertension Control Challenge could help to improve hypertension control rates nationally and decrease the incidence of heart disease and stroke.
  5 in total

1.  An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention.

Authors:  Alan S Go; Mary Ann Bauman; Sallyann M Coleman King; Gregg C Fonarow; Willie Lawrence; Kim A Williams; Eduardo Sanchez
Journal:  J Am Coll Cardiol       Date:  2013-11-15       Impact factor: 24.094

2.  Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC/AHA Hypertension Guideline.

Authors:  Matthew D Ritchey; Cathleen Gillespie; Gregory Wozniak; Christina M Shay; Angela M Thompson-Paul; Fleetwood Loustalot; Yuling Hong
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-09-08       Impact factor: 3.738

3.  Characteristics of Health Care Practices and Systems That Excel in Hypertension Control.

Authors:  An Young; Matthew D Ritchey; Mary G George; Judy Hannan; Janet Wright
Journal:  Prev Chronic Dis       Date:  2018-06-07       Impact factor: 2.830

Review 4.  US trends in premature heart disease mortality over the past 50 years: Where do we go from here?

Authors:  Matthew D Ritchey; Hilary K Wall; Mary G George; Janet S Wright
Journal:  Trends Cardiovasc Med       Date:  2019-09-27       Impact factor: 6.677

5.  Vital Signs: Prevalence of Key Cardiovascular Disease Risk Factors for Million Hearts 2022 - United States, 2011-2016.

Authors:  Hilary K Wall; Matthew D Ritchey; Cathleen Gillespie; John D Omura; Ahmed Jamal; Mary G George
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-09-07       Impact factor: 17.586

  5 in total
  3 in total

1.  Factors Associated With Not Having a Healthcare Visit in the Past Year Among US Adults With Hypertension: Data From NHANES 2013-2018.

Authors:  Oluwasegun P Akinyelure; Demetria Hubbard; Swati Sakhuja; Shakia T Hardy; Suzanne Oparil; Andrea L Cherrington; Kristi Reynolds; Gregory Wozniak; Paul Muntner
Journal:  Am J Hypertens       Date:  2022-02-01       Impact factor: 3.080

2.  Cost-Effectiveness and Cost-Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran.

Authors:  Mohammadreza Amirsadri; Valiollah Hajhashemi; Amir Shahriar Asemi
Journal:  J Res Pharm Pract       Date:  2021-08-03

3.  County-Level Trends in Hypertension-Related Cardiovascular Disease Mortality-United States, 2000 to 2019.

Authors:  Adam S Vaughan; Fátima Coronado; Michele Casper; Fleetwood Loustalot; Janet S Wright
Journal:  J Am Heart Assoc       Date:  2022-03-18       Impact factor: 6.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.